Abstract
The success of genome-wide association studies (GWAS) has significantly advanced our understanding of the etiology of coronary artery disease (CAD) and opens new opportunities to reinvigorate the stalling CAD drug development. However, there exists remarkable disconnection between the CAD GWAS findings and commercialized drugs. While this could implicate major untapped translational and therapeutic potentials in CAD GWAS, it also brings forward extensive technical challenges. In this review we summarize the motivation to leverage GWAS for drug discovery, outline the critical bottlenecks in the field, and highlight several promising strategies such as functional genomics and network-based approaches to enhance the translational value of CAD GWAS findings in driving novel therapeutics
Highlights
Coronary artery disease (CAD) is a leading cause of mortality worldwide [1]
We summarize the state of coronary artery disease (CAD) genome-wide association studies (GWAS)
GWAS has been highly successful in elucidating the genetic architecture of CAD and driving the discovery of novel biology
Summary
Coronary artery disease (CAD) is a leading cause of mortality worldwide [1]. CAD is well recognized as a complex disease with both genetic and environmental contributions [2]. It is of critical importance to form strategies that leverage the recent genetic discoveries from GWAS and other relevant efforts such as multi-dimensional data integration and systems genetics to allow for efficient identification of novel and reliable CAD drug targets.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
